Trial Profile
A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Seliciclib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms APPRAISE
- Sponsors Cyclacel Pharmaceuticals
- 07 Dec 2021 Status changed from completed to discontinued.
- 21 Dec 2010 Primary endpoint 'Progression-free-survival' has not been met, according to a Cyclacel Pharmaceuticals media release.
- 21 Dec 2010 Top-line results reported in a Cyclacel Pharmaceuticals media release.